Blood test and AI team up to outsmart colon cancer recurrence

NCT ID NCT07673393

Not yet recruiting Knowledge-focused Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study explores whether combining artificial intelligence analysis of tumor tissue with special blood tests (liquid biopsy) can more accurately predict if colon cancer will return after surgery. Researchers will follow 400 adults with stage II or III colon cancer for up to five years, comparing the new methods to standard hospital assessments. The goal is to see if these tools can help doctors decide who truly needs chemotherapy and who does not.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this approach could help doctors more accurately identify which patients need chemotherapy after colon cancer surgery and which can safely avoid it.
What could go wrong: This is an observational study, not a treatment trial. The new tests may not prove more accurate than current methods, and results may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colon carcinoma colonic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON ADENOCARCINOMA COLON CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.